Professional Portal

For Investors & Wholesalers

Pre-Acquisition Title Diagnostics for Investors

Understand title risk before committing capital or assuming liability.

Capital Protection Through Diagnostic Intelligence

Diagnostics are paid by the investor or end buyer—not by wholesalers. Pre-acquisition diagnostics document title risk, cure costs, and resolution timelines before capital deployment, enabling data-driven acquisition decisions and risk-adjusted pricing.

Title Rescue Desk is not a law firm and does not provide legal advice. We provide factual diagnostic analysis used by investors and their counsel to assess acquisition risk and determine deal feasibility.

Investor Entry Paths

Deal Stuck Due to Title?

Your deal is in trouble. Title issues have emerged, the closing is at risk, and you're unsure if the deal can be salvaged. Submit your file for an objective assessment of whether this deal can be rescued.

Rescue My Deal

Bring Us the Problem Deal

You have a deal with title problems. Before you walk away or overpay, let us assess what it would actually take to clear this title. Get the real numbers before making your decision.

Submit Problem Deal

Important: Title Rescue Desk is not a law firm and does not provide legal advice. We provide diagnostics and title-readiness services that help investors make informed decisions.

Why Investors Lose Money at Title

Distressed properties often carry title defects that surface only after acquisition—probate gaps, undisclosed liens, tax delinquencies, or chain-of-title breaks that prevent marketable title. Investors who acquire without diagnostic analysis face capital loss when properties cannot be resold or refinanced.

Title insurance may not issue on properties with known defects. Lenders refuse financing on unmarketable title. Legal fees for cure attempts can exceed property value. Holding costs accumulate while title issues remain unresolved.

Pre-acquisition diagnostics reduce this risk. Investors receive written documentation of title defects, estimated cure costs, and resolution timelines before committing capital— enabling informed go/no-go decisions or risk-adjusted purchase price negotiations.

Common Investor Title Losses

  • Acquisition of property with undisclosed liens exceeding purchase price
  • Probate defects discovered post-closing preventing resale
  • Tax deed purchases with redemption rights or title defects
  • Foreclosure remnants with subordinate liens or judgment clouds
  • Legal fees for quiet title actions exceeding expected profit margins
  • Extended holding costs during unresolved title clearing attempts

What a Curative Title Diagnostic Is

Defect Inventory

Systematic documentation of all title impairments—probate gaps, liens, tax issues, chain-of-title breaks, and encumbrances preventing marketable title.

Risk Rating A–D

Each defect assigned risk rating based on curability, legal complexity, estimated cost, and resolution timeline. Ratings inform acquisition risk assessment.

Cure Path or No-Go

Documented resolution pathways (probate, quiet title, administrative) with cost and timeline estimates—or documented determination that property is terminal.

Diagnostic Reports Are Not

  • Legal advice or attorney opinions
  • Title insurance or title guarantees
  • Promises that title can be cured
  • Guarantees of resale success

When to Order a Diagnostic & Who Pays

Optimal Timing

Order diagnostics before closing—not after acquisition. Pre-acquisition diagnostics enable informed go/no-go decisions and risk-adjusted pricing negotiations before capital commitment.

  • During due diligence: After preliminary title review reveals potential defects
  • Before auction commitment: When title status is unclear prior to bidding
  • Pre-contract execution: When seller discloses known title issues
  • Portfolio acquisitions: When bulk purchases include properties with title questions

Who Pays Diagnostic Fees

Diagnostics are paid by the investor or end buyer—not by wholesalers. The party acquiring the property pays the diagnostic fee upfront.

Payment Scenarios

  • End buyer pays diagnostic before closing on wholesale deal
  • Investor pays diagnostic during due diligence phase
  • Fund or institutional buyer pays for portfolio acquisition diagnostics

Diagnostic fees are not contingent on closing. Fee is earned for research and analysis— regardless of whether acquisition proceeds. Some diagnostics conclude deals should be abandoned.

Diagnostic Tiers for Investors

EXPRESS
$495
24-hour turnaround

Rapid Risk Assessment

Fast-track analysis for urgent auction deadlines or contract contingencies requiring immediate go/no-go determination.

  • Primary defect identification
  • High-level risk assessment
  • Terminal defect flagging
STANDARD
$995
48–72 hour turnaround

Comprehensive Due Diligence

Full-depth diagnostic with systematic defect inventory, A–D risk ratings, and documented cure pathways with cost estimates.

  • Complete chain-of-title analysis
  • Risk rating per defect
  • Cost and timeline estimates
INSTITUTIONAL
Custom
Volume pricing

Portfolio Acquisitions

Master Service Agreements for funds and institutional buyers requiring volume diagnostic support with defined SLAs.

  • Volume-based pricing
  • Priority processing
  • Dedicated account management

What a Walk-Away Determination Means

Not all properties can achieve marketable title. Some title defects are terminal—impossible or economically impractical to cure. When diagnostic analysis reveals such defects, we document this as a no-go determination with supporting reasoning.

Walk-away determinations protect investor capital by providing documented justification for abandoning acquisitions where cure costs exceed property value, legal remedies are unavailable, or resolution timelines are indefinite.

The diagnostic fee is earned for clarity—not for positive outcomes. Investors pay for research and analysis that sometimes reveals a property should not be acquired. This clarity prevents larger capital losses post-acquisition.

Terminal Defect Examples

  • Probate defects with missing heirs or disputed wills preventing clear ownership chain
  • Lien encumbrances exceeding property value with no subordination available
  • Tax deed purchases with unextinguished redemption rights or adverse possession claims
  • Chain-of-title breaks with no documentary evidence of conveyance available
  • Quiet title actions requiring extensive litigation with uncertain outcomes

No guarantee of resolution. Diagnostics document title risk and potential resolution pathways— not guarantees of successful cure. Walk-away determinations are a documented outcome protecting investor capital from properties that cannot economically achieve marketable title.

Ready to Order a Pre-Acquisition Diagnostic?

Protect your capital with documented title risk analysis before closing.